文献速递头颈部肿瘤放疗姑息放疗与转移瘤

新诊断寡转移鼻咽癌患者放疗及转移灶局部治疗的长期疗效分析:一项前瞻性、单臂、单中心临床研究

Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
PubMed 文献 · Radiother Oncol · 2024-04-05

这项单中心、单臂前瞻性研究纳入51例新诊断寡转移鼻咽癌患者,在铂类姑息化疗达到疾病控制后接受鼻咽及颈部根治性放疗和转移灶局部治疗。中位随访60个月,中位总生存期(OS)和无进展生存期(PFS)分别为53.87个月和24.23个月,放疗后维持治疗与PFS改善相关。

要点

  • 中位随访60个月,中位OS为53.87个月,中位PFS为24.23个月。
  • 放疗后维持治疗与PFS延长相关(36.43 vs 16.1个月,P=0.005)。
  • 单器官转移患者OS优于双器官转移患者(P=0.001)。

核心结论

  • 新诊断寡转移鼻咽癌患者在接受原发灶根治性放疗和转移灶局部治疗后能够获得长期生存。

研究设计与样本

  • 单中心、单臂前瞻性临床研究(NCT03129412),最终分析纳入51例新诊断寡转移鼻咽癌患者。

主要发现

  • 中位随访60个月,中位OS为53.87个月,中位PFS为24.23个月。
  • 1年、3年、5年PFS率分别为76.5%、38.1%、31.8%,1年、3年、5年OS率分别为98%、75.4%、45.6%。
  • 单因素和多因素分析均显示放疗后维持治疗可显著延长PFS(36.43 vs 16.1个月,P=0.005)。
  • 单器官转移患者OS显著优于双器官转移患者(P=0.001)。
  • 多因素分析显示转移器官数量也显著影响PFS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted a single-center, single-arm study (NCT03129412) to prospectively analyze the long-term outcomes of newly diagnosed patients with oligometastatic nasopharyngeal carcinoma (NPC) who received radical radiotherapy and local treatment of metastases. PATIENTS AND METHODS: Patients who reached disease controll after platinum-based palliative chemotherapy continued to receive radical radiotherapy for the nasopharyngeal region and neck. Appropriate local treatments were selected to treat the metastatic lesions. The primary endpoint of this study was overall survival (OS) and the secondary endpoint was progression-free survival (PFS). RESULTS: Fifty-one patients were included in the final analysis. During a median follow-up of 60 months, the median OS and PFS were 53.87 and 24.23 months, respectively. The 1-year, 3-year, and 5-year PFS and OS rates were 76.5 %, 38.1 %, and 31.8 % and 98 %, 75.4 %, 45.6 %, respectively. Both single and multivariate analysis indicated that maintenance therapy after radiotherapy could significantly increase PFS (36.43 vs. 16.1 months, P = 0.005). The OS of patients with single organ metastasis was significantly better than that of patients with double organ metastasis (P = 0.001). In addition, the number of metastatic organs also significantly affected PFS in the multifactor analysis. CONCLUSION: Patients with newly diagnosed oligometastatic NPC can achieve long-term survival after receiving radical radiotherapy to the primary site and local treatment for metastases.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang S, Jiang F, Cao C, et al. Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study. Radiother Oncol. 2024. PMID: 38583720. doi:10.1016/j.radonc.2024.110265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。